ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Rhea-AI Summary

ASLAN Pharmaceuticals (Nasdaq: ASLN) announced that Dr. Carl Firth, CEO, will participate in one-on-one meetings and a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023. The fireside chat is scheduled for 10:30am EST. An on-demand recording will be available on ASLAN's website. ASLAN is developing innovative treatments for autoimmune conditions, including eblasakimab and farudodstat.

SAN MATEO, Calif. and SINGAPORE, March 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will be available for one-on-one meetings and participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023. Details for the fireside chat are as follows:

Date: Thursday, March 30, 2023

Time: 10:30am EST

An on demand recording of the fireside chat will be available in the Investor Relations section of ASLAN’s website or can be accessed directly at this link.

Please contact your H.C. Wainwright representative to request a one-on-one meeting with management.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease. Eblasakimab is being investigated in a global Phase 2b trial of moderate-to-severe AD patients with topline readout expected in early July 2023. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme DHODH, as a first-in-class treatment for alopecia areata (AA) and plans to initiate a proof-of-concept trial in 2Q 2023. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the website or follow ASLAN on LinkedIn.

Media and IR contacts

Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com

Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com

 

FAQ

What is the date of ASLAN Pharmaceuticals' fireside chat at the H.C. Wainwright Conference?

The fireside chat will take place on March 30, 2023.

What time is Dr. Carl Firth's fireside chat scheduled for?

The fireside chat is scheduled for 10:30am EST.

Where can I watch the recording of the fireside chat for ASLAN Pharmaceuticals?

The recording will be available on ASLAN's Investor Relations section of their website.

What innovative treatments is ASLAN Pharmaceuticals developing?

ASLAN is developing eblasakimab for atopic dermatitis and farudodstat for alopecia areata.

When is the topline readout expected for eblasakimab's trial?

The topline readout for eblasakimab is expected in early July 2023.